A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
Status:
Active, not recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to
improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's
overall survival (OS) is superior to placebo.